Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • PB1897: DISCONTINUATION OF IMA...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
PB1897: DISCONTINUATION OF IMATINIB IN PATIENTS FOLLOWED FOR CHRONIC MYELOID LEUKEMIA IN DEEP MOLECULAR RESPONSE

PB1897: DISCONTINUATION OF IMATINIB IN PATIENTS FOLLOWED FOR CHRONIC MYELOID LEUKEMIA IN DEEP MOLECULAR RESPONSE

Bibliographic Details
Main Authors: Y. Bouchakor Moussa, S. Taoussi, S. Oukid, F. Lamraoui, N. Rekab, K. M. Benlabiod, H. Brahimi, M. T. Abad, M. Bradai
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000850440.38789.88
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/01.HS9.0000850440.38789.88

Similar Items

  • Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia
    by: Naoto Takahashi, et al.
    Published: (2012-06-01)
  • Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
    by: Alexandra Rodrigues Alves, et al.
  • Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia
    by: Malkan Umit Y., et al.
    Published: (2018-12-01)
  • Peripheral lymphocyte subsets as predicting factors for molecular recurrence after imatinib discontinuation in a phase 2 imatinib discontinuation trial in patients with chronic myeloid leukemia
    by: Arthur Gomes Oliveira Braga, et al.
    Published: (2024-07-01)
  • Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia
    by: Seiichiro Katagiri, et al.
    Published: (2017-01-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs